Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.68 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.68 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.68 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.68 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31637136 | 0.91 | SLC28A1 (0.68) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL16340739 | 0.90 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL26632568 | 0.90 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL6061102 | 0.90 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL703999 | 0.90 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL5561744 | 0.90 | SLC28A1 (0.70) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL13737068 | 0.87 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL6141707 | 0.87 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL547063 | 0.87 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL1495212 | 0.87 | SLC28A1 (0.65) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090299049-A1 | Bicyclic Compounds and Their Use | REPLIZYME LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| EP-1984455-A2 | BICYCLIC COMPOUNDS AND THEIR USE | THE UNIVERSITY OF YORK (GB) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007091056-A2 | BICYCLIC COMPOUNDS AND THEIR USE | THE UNIVERSITY OF YORK (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299049-A1 | Bicyclic Compounds and Their Use | ERCC4, PARP1, ERCC5 | SLC28A1 169/4885SLC28A2 225/4885SLC29A1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.